Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

NCT00660595 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00660595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00660595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2008
Completion date
December 31, 2008
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenic disorders